Lastly, Cramer expects "marijuana-adjacent" biotechnology companies like GW Pharmaceuticals and Corbus Pharmaceutical Holdings to start getting more credit from investors for their cannabis-influenced businesses.
"These are not pot companies. They are drug companies focused on developing artificial cannabinoids that mimic what cannabis does to your body," he explained. GW Pharmaceuticals develops cannabis-plant-derived treatments for diseases including epilepsy.
"Why do I see these stocks benefiting? Because as cannabis companies try to push clinical trials for medicinal marijuana, ... I think they're going to run into one big problem [with] dosing," Cramer said.
Because cannabis is a plant, there tends to be a lot of variability when it comes to THC and CBD levels in each batch. But GW and Corbus' treatments don't have that problem, he argued.
"As we get more and more data showing the efficacy of medicinal marijuana, I think more investors will embrace actual medicines that do the same thing as marijuana, but they do it more reliably," he said.